Dr. Reddy's Semaglutide Batch Fails OOS Test on API Issue, Shares Slide 4%

An out-of-specification finding at the API level threatens timelines and regulatory standing for Dr. Reddy's flagship GLP-1 asset, raising supply-chain and quality-control concerns in a fiercely competitive obesity drug race.

ndtv-profit-business · 7/9/2026, 6:01:15 AM · Ask about this →